Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sourcinglink.Net Inc (SNET)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,758
  • Shares Outstanding, K 123,121
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta 2.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0102 +145.10%
on 03/06/19
0.0250 unch
on 03/26/19
+0.0114 (+83.82%)
since 02/26/19
3-Month
0.0060 +316.67%
on 02/26/19
0.0250 unch
on 03/26/19
+0.0147 (+142.72%)
since 12/24/18
52-Week
0.0050 +400.00%
on 04/20/18
0.0250 unch
on 03/26/19
+0.0147 (+142.72%)
since 03/23/18

Most Recent Stories

More News
Therapies Trying to Fight Against Cancer

Over the past two decades, U.S. cancer-related deaths have significantly declined. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American Cancer...

AGEN : 2.96 (+4.59%)
APTO : 2.23 (-1.76%)
INO : 3.73 (+3.04%)
GILD : 64.24 (+0.71%)
CVM : 3.06 (+1.32%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0250 (+11.61%)
APS.TO : 2.99 (-1.32%)
Therapies Trying to Fight Against Cancer

Over the past two decades, U.S. cancer-related deaths have significantly declined. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American Cancer...

AGEN : 2.96 (+4.59%)
APTO : 2.23 (-1.76%)
INO : 3.73 (+3.04%)
GILD : 64.24 (+0.71%)
CVM : 3.06 (+1.32%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0250 (+11.61%)
APS.TO : 2.99 (-1.32%)
SourcingLink.net Enters into an Exclusive Worldwide Licensing Agreement with NanoSmart Pharmaceuticals for Anti-Nuclear Antibody (ANA)-Targeted Doxorubicin Formulations to Treat Cancer

via NEWMEDIAWIRE - SourcingLink.net, Inc. (SNET), announced today that it entered into an exclusive worldwide licensing agreement with NanoSmart Pharmaceuticals, Inc. for the right to use NanoSmart's nanoparticle...

SNET : 0.0250 (+11.61%)
SNETD : 0.3900 (+14.71%)
Biotech Companies Turn Their Attention to Cancer as Global Incidences Grow

In 2018, cancer was the second leading cause of death around the globe. Cancer was responsible for an estimated 9.6 million deaths in that year, or approximately one in six deaths, according to the World...

CANF : 0.93 (-27.91%)
CYCC : 0.92 (-3.14%)
ONCS : 0.49 (-1.40%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0250 (+11.61%)
BLRX : 0.43 (-2.21%)
Biotech Companies Intensify Research Into New Therapies to Combat Cancer

Cancer ranks among one of the top causes of death globally and data show that the number is still expected to increase. The National Cancer Institute stated in 2012 there were 14.1 million new cases of...

AST : 0.94 (unch)
NWBO : 0.2850 (-1.72%)
GNCA : 0.62 (+1.67%)
CYTR : 0.72 (-3.63%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0250 (+11.61%)
Many Look Beyond Chemotherapy to Combat the Swelling Incidence of Cancer

In 2018, the World Health Organization estimated that the global incidence of cancer rose to 18.1 million new cases and 9.6 million deaths. The statistics show that at least 1 in 5 men and 1 in 6 women...

ADXS : 0.48 (-4.76%)
AVEO : 0.57 (unch)
OMED : 0.98 (+2.76%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0250 (+11.61%)
ATNM : 0.48 (+2.13%)
Demand for Cancer Treatment Remains High Despite Improving Survivability Rates

Deaths related to cancer dropped by 27% in the past quarter-century, meaning that 2.6 million fewer people died due to cancer during that time period, according to a report by the American Cancer Society....

ABIO : 0.39 (+2.79%)
SESN : 0.90 (+3.32%)
NAVB : 0.15 (+7.14%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0250 (+11.61%)
CGIX : 0.25 (-3.77%)
SourcingLink.net to Investigate the Potential of Combining its Novel Autologous Immune-Therapy with Synergistic Oncology Therapies

via NEWMEDIAWIRE -- SourcingLink.net (OTC PINK: SNET), based in San Francisco, is a pioneering biotech company focused on oncology . The company is developing its proprietary autologous immune-therapy...

SNET : 0.0250 (+11.61%)
SourcingLink.net to Leverage Pharmacogenomics in Its Oncology Therapy Development and Clinical Trial Program

via NEWMEDIAWIRE -- SourcingLink.net (OTC PINK: SNET) is announcing that it will harness the power of pharmacogenomics in its oncology therapy development and clinical trials. Pharmacogenomics studies...

SNET : 0.0250 (+11.61%)
Safer Treatments Gain Market Traction as Cancer Occurence Continues to Grow

FinancialBuzz.com News Commentary

RNN : 0.53 (-1.85%)
OGEN : 0.59 (-1.67%)
ONCS : 0.49 (-1.40%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0250 (+11.61%)
SNSS : 1.20 (-6.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

See More Share

Trade SNET with:

Key Turning Points

2nd Resistance Point 0.0283
1st Resistance Point 0.0267
Last Price 0.0250
1st Support Level 0.0217
2nd Support Level 0.0183

See More

52-Week High 0.0250
Last Price 0.0250
Fibonacci 61.8% 0.0174
Fibonacci 50% 0.0150
Fibonacci 38.2% 0.0126
52-Week Low 0.0050

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar